Enumerix

📍 Palo Alto, United States🗓 Founded 2019👥 34 employees💰 Last funded Mar 2024
Biotechnology
LinkedIn
In an era of ever-increasing cost and skills required to do complex diagnostics tests, Enumerix is developing a next-generation genomics platform to make high resolution biology simple, fast, and affordable. Our goal is to reduce the cost of high resolution tests by at least 10 times to enable access to a broader patient population. We believe our team is poised to accomplish this. We are a group of seasoned biotech and innovative entrepreneurs, engineers, and scientists with a proven track record of advancing the field of genomics from innovation to commercial success. We have pioneered DNA microarrays, non-invasive prenatal screening using next generation sequencing (NGS), and high-throughput single-cell NGS, and together the founding team holds over 60 granted patents.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Enumerix?
Enumerix has 2 investors on record on gritt.io, 2 mid-stage.
When did Enumerix last raise funding?
The most recent investment in Enumerix recorded on gritt.io was in March 2024.
When was Enumerix founded?
Enumerix was founded in 2019.
What industry is Enumerix in?
Enumerix operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Enumerix based?
Enumerix is headquartered in Palo Alto, United States.